Clinical Trial

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

Study acronym: ATICC
Recruiting
View on ClinicalTrials.gov →
Summary
\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge. Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-12; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2024-03-12
Trial Details
NCT Number NCT06083103
Lead Sponsor Centre Paul Strauss
Conditions Cervical Cancer
Enrollment 50 participants
Start Date 2023-10-12
Primary Completion 2026-09-11 (estimated)
Study Completion 2026-09-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-02